Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Indacaterol + Glycopyrronium
Indication
Maintenance therapy in COPD.
Instruction
1 cap once daily via inhaler device.
Drug interaction
Indacaterol: May potentiate hypokalaemic effect with xanthine derivatives, steroids, diuretics. May potentiate CV effects with MAOIs, TCA, QTc-prolonging agents. May cause sever bronchospasm with β-blockers. Glycopyrronium: Increased adverse effects with other anticholinergic drugs.
NOVARTIS PHARMA STEIN AG
Contents
Indacaterol + Glycopyrronium
Indication
Maintenance therapy in COPD.
Instruction
1 cap once daily via inhaler device.
Drug interaction
Indacaterol: May potentiate hypokalaemic effect with xanthine derivatives, steroids, diuretics. May potentiate CV effects with MAOIs, TCA, QTc-prolonging agents. May cause sever bronchospasm with β-blockers. Glycopyrronium: Increased adverse effects with other anticholinergic drugs.
Inquiry - Xoterna Breezhaler 110/50mcg Inhalation Powder Hard Capsule